2. Academic Validation
  3. In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli

  • Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01832-18. doi: 10.1128/AAC.01832-18.
James A Karlowsky 1,  Heather J Adam 1,  Melanie R Baxter 1,  Andrew J Denisuik 1,  Philippe R S Lagacé-Wiens 1,  Andrew J Walkty 1,  Sailaja Puttagunta 2,  Michael W Dunne 2,  George G Zhanel 3
Affiliations

Affiliations

  • 1 Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
  • 2 Iterum Therapeutics, Old Saybrook, Connecticut, USA.
  • 3 Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada [email protected].
PMID: 30397056 DOI: 10.1128/AAC.01832-18
Abstract

The in vitro activity of sulopenem was assessed against a collection from 2014 to 2016 of 539 urinary isolates of Escherichia coli from Canadian patients by using CLSI-defined broth microdilution methodology. A concentration of sulopenem 0.03 µg/ml inhibited both 50% (MIC50) and 90% (MIC90) of isolates tested; sulopenem MICs ranged from 0.015 to 0.25 µg/ml. The in vitro activity of sulopenem was unaffected by nonsusceptibility to trimethoprim-sulfamethoxazole and/or ciprofloxacin, multidrug-resistant phenotypes, extended-spectrum β-lactamases, or AmpC β-lactamases.

Keywords

Escherichia coli; penem; sulopenem; urinary.

Figures
Products